Skip to content
Triangle logo TriangleGet started
← Study library

NCT00004088 · REGISTRY CONDITION SEARCH

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-07-02

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies, such as interferon alfa, use different ways to stimulate the immune system and stop cancer cells from growing. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. Pamidronate may help to reduce the side effects of treatment for multiple myeloma. PURPOSE: This phase II trial is studying combination chemotherapy, peripheral stem cell transplantation, biological therapy, pamidronate, and thalidomide to see how well they work in treating patients with stage I, stage II, or stage III multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Best Response Prior to Tandem Autologous Stem Cell Transplant

→

outcome · POSTED

Response After Tandem Autologous Stem Cell Transplant

→

outcome · POSTED

Three-year Overall Survival

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Best Response at 6 Months Post Tandem Autologous Stem Cell Transplant

→

outcome · POSTED

Best Response After Tandem Autologous Stem Cell Transplant and Maintenance

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Histologically proven stage I-III multiple myeloma * Less than 18 months since diagnosis * Smoldering myeloma allowed if there is evidence of progressive disease requiring therapy * At least 25% increase in M protein levels or Bence Jones excretion * Hemoglobin no greater than 10.5 g/dL * Hypercalcemia * Frequent infections * Rise in serum creatinine above normal on 2 separate occasions * Nonquantifiable monoclonal proteins allowed if other criteria for multiple myeloma or smoldering myeloma are met * Response/status after induction therapy: * Responding or stable disease AND no greater than 40% myelomatous involvement of bone marrow * No Waldenstrom's macroglobulinemia PATIENT CHARACTERISTICS: Age: * 65 and under Performance status: * Karnofsky 80-100% Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics * Absolute neutrophil count greater than 1,500/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * Serum glutamic axaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2.5 times upper limit of normal * Hepatitis B antigen or hepatitis C ribonucleaic acid (RNA) negative Renal: * See Disease Characteristics * Creatinine no greater than 1.4 mg/dL * Creatinine clearance greater than 65 mL/min Cardiovascular: * Cardiac ejection fraction at least 50% by multigated acquisition scan (MUGA) or echocardiogram Pulmonary: * Forced-expiratory volume in one second (FEV\_1) greater than 60% of normal * Diffusing capacity for carbon monoxide (DLCO) greater than 50% of predicted lower limit Other: * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * Human immunodeficiency virus (HIV) negative * No other medical or psychosocial problems that would increase patient risk * No other malignancy within past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix * No known hypersensitivity to filgrastim (G-CSF) or Escherechi coli-derived proteins PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * No more than 3 prior chemotherapy regimens * At least 4 weeks since prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 4 weeks since prior radiotherapy Surgery: * Not specified
healthy Volunteers
false
maximum Age
65 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive high-dose (HD) melphalan intra-venously (IV) on day -1. Peripheral blood progenitor cells (PBPCs) are reinfused on day 0. Filgrastim (G-CSF) is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive IV high-dose busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBPCs are reinfused on day 0 and G-CSF is administered IV or subcutaneously (SC) daily until blood counts recover.
    intervention Names
    1. Biological: filgrastim
    2. Biological: recombinant interferon alfa
    3. Drug: busulfan
    4. Drug: cyclophosphamide
    5. Drug: melphalan
    6. Drug: pamidronate disodium
    7. Drug: thalidomide
    8. Procedure: peripheral blood stem cell transplantation
    label
    HD chemotherapy followed by PBPC Rescue
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    filgrastim
    other Names
    1. granulocyte colony-stimulating factor (G-CSF)
    2. Neupogen
    type
    BIOLOGICAL
  2. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    recombinant interferon alfa
    other Names
    1. IFN alpha-2B
    2. Intron A
    type
    BIOLOGICAL
  3. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    busulfan
    other Names
    1. Myleran
    2. Busulfex
    type
    DRUG
  4. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    cyclophosphamide
    other Names
    1. cytophosphane
    2. Cytoxan
    type
    DRUG
  5. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    melphalan
    other Names
    1. Alkeran
    2. Evomela
    type
    DRUG
  6. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    pamidronate disodium
    other Names
    1. pamidronic acid
    type
    DRUG
  7. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    thalidomide
    other Names
    1. Thalidomid
    2. Immunoprin
    type
    DRUG
  8. arm Group Labels
    1. HD chemotherapy followed by PBPC Rescue
    name
    peripheral blood stem cell transplantation
    other Names
    1. peripheral blood progenitor cell transplantation
    type
    PROCEDURE
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
77
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Response gradations are specified in the "Blade criteria", Br J Haematol 1998; 102: 1115-1123. Serum myeloma protein is measured 2x at least six weeks apart, and urine M-component is measured 2x at least 3 weeks apart. Complete response (CR): less than 3% plasma cells in bone marrow or blood. Very good partial response (VGPR): Greater than 90% decrease in myeloma protein, and urine M-component less than 0.1 gm/day. Partial response (PR) Greater than 50% decrease in myeloma protein; urine M-component less than 0.2 gm/day. Lytic skeletal lesions must not increase, and serum calcium level must remain normal. Stable disease (SD): 25-49% decrease in protein and 25% decrease in urine M-component. Progressive disease (PD): Greater than 25% increase in myeloma protein, or hypercalcemia. Relapse: 1) increase greater than 100% of myeloma protein; 2) More than 25% increase of myeloma protein; 3) reappearance of the myeloma peaks; 4) increase in lytic bone lesions on radiographs.
    measure
    Best Response Prior to Tandem Autologous Stem Cell Transplant
    time Frame
    From enrollment in the study until day -8: before dilantin given pre-first high-dose chemo preceeding first cycle of tandem autologous cell transplant
  2. description
    Response gradations are specified in the "Blade criteria", Br J Haematol 1998; 102: 1115-1123. Serum myeloma protein is measured 2x at least six weeks apart, and urine M-component is measured 2x at least 3 weeks apart. Complete response (CR): less than 3% plasma cells in bone marrow or blood. Very good partial response (VGPR): Greater than 90% decrease in myeloma protein, and urine M-component less than 0.1 gm/day. Partial response (PR) Greater than 50% decrease in myeloma protein; urine M-component less than 0.2 gm/day. Lytic skeletal lesions must not increase, and serum calcium level must remain normal. Stable disease (SD): 25-49% decrease in protein and 25% decrease in urine M-component. Progressive disease (PD): Greater than 25% increase in myeloma protein, or hypercalcemia. Relapse: 1) increase greater than 100% of myeloma protein; 2) More than 25% increase of myeloma protein; 3) reappearance of the myeloma peaks; 4) increase in lytic bone lesions on radiographs.
    measure
    Response After Tandem Autologous Stem Cell Transplant
    time Frame
    After second cycle of tandem autologous stem cell transplant: Day 0 of second transplant to 12 weeks post-cycle 2 cell infusion of the tandem transplant.
  3. description
    Kaplan-Meier estimate at three years post-first transplant of survival. Outcome is death or alive at follow-up (censored). 95 percent confidence interval of the point estimate is calculated using Greenwood's variance.
    measure
    Three-year Overall Survival
    time Frame
    Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.
  4. description
    Kaplan-Meier estimate at three years post-first transplant of survival. Event of interest is the first of Death or Progression. Censoring is Alive in Continuous Complete Remission at date of last follow-up. 95 percent confidence interval of the point estimate is calculated using Greenwood's variance.
    measure
    Progression-free Survival
    time Frame
    Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.
  5. description
    Response gradations are specified in the "Blade criteria", Br J Haematol 1998; 102: 1115-1123. Serum myeloma protein is measured 2x at least six weeks apart, and urine M-component is measured 2x at least 3 weeks apart. Complete response (CR): less than 3% plasma cells in bone marrow or blood. Very good partial response (VGPR): Greater than 90% decrease in myeloma protein, and urine M-component less than 0.1 gm/day. Partial response (PR) Greater than 50% decrease in myeloma protein; urine M-component less than 0.2 gm/day. Lytic skeletal lesions must not increase, and serum calcium level must remain normal. Stable disease (SD): 25-49% decrease in protein and 25% decrease in urine M-component. Progressive disease (PD): Greater than 25% increase in myeloma protein, or hypercalcemia. Relapse: 1) increase greater than 100% of myeloma protein; 2) More than 25% increase of myeloma protein; 3) reappearance of the myeloma peaks; 4) increase in lytic bone lesions on radiographs.
    measure
    Best Response at 6 Months Post Tandem Autologous Stem Cell Transplant
    time Frame
    Six months after day 0 of the first cycle of the tandem autologous stem cell transplant. This will be used to determine administration of thalidomide.
  6. description
    Response gradations are specified in the "Blade criteria", Br J Haematol 1998; 102: 1115-1123. Serum myeloma protein is measured 2x at least six weeks apart, and urine M-component is measured 2x at least 3 weeks apart. Complete response (CR): less than 3% plasma cells in bone marrow or blood. Very good partial response (VGPR): Greater than 90% decrease in myeloma protein, and urine M-component less than 0.1 gm/day. Partial response (PR) Greater than 50% decrease in myeloma protein; urine M-component less than 0.2 gm/day. Lytic skeletal lesions must not increase, and serum calcium level must remain normal. Stable disease (SD): 25-49% decrease in protein and 25% decrease in urine M-component. Progressive disease (PD): Greater than 25% increase in myeloma protein, or hypercalcemia. Relapse: 1) increase greater than 100% of myeloma protein; 2) More than 25% increase of myeloma protein; 3) reappearance of the myeloma peaks; 4) increase in lytic bone lesions on radiographs.
    measure
    Best Response After Tandem Autologous Stem Cell Transplant and Maintenance
    time Frame
    Response after six months after day 0 of the first cycle of the tandem transplant, after administration of maintenance thalidomide if necessary, until three years post-day 0 of the first cycle of the tandem transplant.
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies, such as interferon alfa, use different ways to stimulate the immune system and stop cancer cells from growing. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. Pamidronate may help to reduce the side effects of treatment for multiple myeloma. PURPOSE: This phase II trial is studying combination chemotherapy, peripheral stem cell transplantation, biological therapy, pamidronate, and thalidomide to see how well they work in treating patients with stage I, stage II, or stage III multiple myeloma.
detailed Description
OBJECTIVES: * Determine the feasibility and toxic effects of high-dose melphalan, busulfan, and cyclophosphamide followed by autologous peripheral blood stem cell rescue, interferon alfa, and pamidronate in patients with responsive or stable, low-bulk multiple myeloma. * Determine the response rate and progression-free and overall survival of patients treated with this regimen. * Determine the feasibility of adding thalidomide to interferon alfa and pamidronate in patients who are not in complete remission (CR) 6 months after the second course of high-dose chemotherapy. * Determine whether administration of thalidomide can increase the CR rate in patients who are not in CR 6 months after the second course of high-dose chemotherapy and determine its effect on progression-free and overall survival of these patients. * Determine the pharmacokinetics of busulfan and cyclophosphamide and correlate the pharmacokinetics with the toxic effects of these drugs and outcome in these patients. * Determine the effect of thalidomide on microvascular density of bone marrow and correlate these possible effects with outcome in these patients. * Determine the cytogenetics, gene rearrangement, and fluorescence in situ hybridization in baseline and post treatment bone marrow and blood specimens and correlate the presence/persistence of these features with treatment outcome in these patients. OUTLINE: Patients receive cyclophosphamide IV over 2 hours on day 1 and filgrastim (G-CSF) subcutaneously (SC) or IV twice a day beginning on day 2 and continuing until peripheral blood stem cells (PBSCs) are collected. PBSCs are collected beginning on day 10. Patients receive high-dose melphalan IV on day -1. PBSCs are reinfused on day 0. G-CSF is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive high-dose busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBSCs are reinfused on day 0 and G-CSF is administered IV or SC daily until blood counts recover. Patients with responding or stable disease after chemotherapy receive maintenance therapy with interferon alfa beginning 14-20 weeks after day 0 of the second course of chemotherapy. Interferon alfa is administered SC 3 times a week for 3 years. Patients also receive pamidronate IV every 4 weeks until disease progression. Patients who are not in complete remission (CR) 6 months after completing the second course of chemotherapy receive oral thalidomide daily for a maximum of 1 year or for 3 months after achieving CR. Patients are followed monthly for 1 year, every 3 months for 1 year, and then periodically thereafter. PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study within approximately 2.5 years.
Source references
references
  1. citation
    Long-term Progression-free (PFS) and Overall Survival (OS) with Tandem Autologous Transplant (TASCT) After High-dose Induction With Melphalan (MEL) and Busulfan/cyclophosphamide (BU/CY), or a Novel Regimen of MEL and Total Marrow Irradiation (TMI), Followed by Maintenance With Interferon A-2 (IF) and/or Thalidomide (THAL). Haematologica 96(s1), 2011, s103. G. Somlo, J. Palmer, A. Dagis, M. O'Donnell, D. Snyder, F. Sahebi, N. Kogut, A. Brown, R. Spielberger, P.Parker, C. Karanes, L. Popplewell, A. Stein, A. Krishnan, J. Alvarnas, J. Wong, S. Forman.
    type
    BACKGROUND
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e7da8bbcf00efafe2155
      requested nct id
      NCT00004088
      primary nct id
      NCT00004088
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      7ec8ba9ded90c2cc2eeb7a27ff4f5be4f7ead97d037eddf7c0da06c862d0ff38
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e7da8bbcf00efafe2155
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00004088
      occurrences
      1. context exact
        NCT00004088
        end
        11
        exact text
        NCT00004088
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/532/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1b4a4f31c73ddb84e0546bf600dde6b0ab011ee8c3ff1b69b9a14ba34ac346ac

    Preserved source evidence · Not medical advice